Member Info for Cloudy390

Especially as it works, by experts, of course.

Just shows the market for a superior product as stated by experts. do some reasearch!

I thought TLZS 501 will be human trials as soon as they get gmp product and nebuliser, early next year. Monkey trials are now apparently.

The R&D news could be trial of TZLS 501 nebulised in monkeys as they stated would happen along side gpm drug manufacture and nebuliser manufacture, perhaps they are trialing it now.

After reading it this screamed at me.
Another potential limitation, or question, is the treatment’s bioavailability, she said. Normally, monoclonal antibody therapies are injected through the bloodstream.

“We know that the most important parts of the infection of coronavirus happens in the lungs … So how much of that antibody that you inject into the bloodstream will actually make it to the place where most of the infection is playing out, which would be the lungs,” she continued

Why hasn’t our method been plastered all over the news, Crazy.

Right we are here now, things are going to happen, all have been said, plain sailing now, trials start, nda trials,then Covid trials start, then news alz trials then main listing. The pudding is about to be tasted, over the next few months of course.oh I forgot about StemprintER.

All what was said was going to happen will be happening. Money was the only sticking point,they have the money so now we progress ,from now to end of Q1 2021 a whole lot of things will be happening. There’s an f..ing great shark coming to restore balance to it all.

Don’t underestimate the US they have access to the lot now!

As the board have said , the markets haven’t recognised the true value.

The Royal Marsden has trialed StemprintER and are impressed ASCO are impressed ,so what’s the problem ,2.8 Bill is in the past ,now 5 Bill.

I would imagine there will be a fund raising on demerger to further StemprintER career in Accustem Plc. So will not be a drain on tils funds as on demerger tils can’t give them money they need it to advance the Crown Jewels. So all makes sense to me. Although I’m a bit confused at the mo.lol

Are adr’s now 1 for 1

I’m a bit confused about a sentence in the RNS it says,
. The Company initially entered into a world-wide exclusive license from Novimmune, SA., a Swiss Biotechnology company in 2017. The license is currently maintained with Bristol Myers Squibb.
So does that mean we are in partnership already with Bristol Meyers Squibb???

Our Chairman is also a major shareholder in Okyo in fact has controlling share.

And so he should have. As I understand he has been sold cheap before, so he knows the tricks now and I am sure he won’t part with this for a song. The only people who have a hard time is shareholders who can’t make up there mind to stand buy there judgement

They’ve got the money, they can now prove proof of concept,happy days and f...k the moaners, short, sell do what you like, but this is going to finish what it started.??

Just a thought, as we are under confidentially agreements , do we have to state when the trials have started. If not , could be near completion.

Amazed. Didn’t realise Foralumab can be used for Covid. Dr Wiener said as we have completed toxicity trials, we can go straight into patient trials, which we are going to do. Another string to the bow!

Hallelujah praise the lord, we shall all be saved, and I mean that most sincere!.

Wouldn’t that be a gas , we would all remember!